Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:1148 (14 May), doi:10.1136/bmj.330.7500.1148
| The first 150 words of the full text of this article appear below. |
EDITORGunnell et al's report on suicide risk with selective serotonin reuptake inhibitors (SSRIs) raises several issues.1
Firstly, clinicians have observed that the first weeks of treatment of severe depression with an antidepressant are accompanied by a higher risk of suicide because of a drug induced motor disinhibition that is not yet accompanied by mood improvement.2
Secondly, the authors' finding of a trend towards a protective effect of SSRIs against suicidal thoughts (odds ratio 0.77) compared with a trend towards an increased risk of self harm (odds ratio 1.57) is paradoxical.
More surprising is the heterogeneity of results among SSRIs. Why would sertraline show a protective effect for suicidal thoughts and simultaneously increase the risk of self harm? The risk difference between citalopram and its active S-enantiomere, escitalopram, is also strange. No strong biological rationale can explain such heterogeneity among drugs with the same mechanism of action.
Thirdly, the
François Curtin, consultant
francoiscurtin@bluemail.ch
Clinical Psychopharmacology Unit, University of Geneva, 2 Ave du Petit-Bel-Air, CH-1225 Chene-Bourg/Geneva, Switzerland
Pierre Schulz, head
Clinical Psychopharmacology Unit, University of Geneva, 2 Ave du Petit-Bel-Air, CH-1225 Chene-Bourg/Geneva, Switzerland